Under the Memorandum of Understanding (MOU), the Asian Eye Institute (AEI) will provide clinical trial expertise to Novotech-managed studies. “Philippines with a population of 107 million is well established as a premier clinical research location,” John Moller, CEO of Novotech, told us.
The AEI serves 60,000 patients in modern facilities. Moller said Novotech can offer clients “faster start-up times and access to the AEI patient database, and leading principal investigators.”
Novotech has offices and teams across the Asia-Pacific region, and has relationships with major hospitals the can benefit clients like the AEI, according to the company.
“Strong site connections works in synergy with our on-the-ground operations, which lead to stronger understanding of the market, standards of care and higher quality feasibility analysis,” explained Moller.
Established in 1996, Novotech is headquartered in Australia and has offices in 11 countries across the pacific region, many of which have MOU’s with health care providers.
Clinical trials in Asia-Pacific
Novotech has several partnerships with medical institutions across Asia to accelerate clinical research. Additionally, in 2013, the CRO opened two clinical research sites in Hong Kong and the Philippines.
Earlier this year, Novotech signed an MOU with the China Medical University Hospital in Taiwan. Similarly to the MOU with the AEI, the agreement provides Novotech’s team with, “professional and medical trial advice.”
“Novotech is committed to establishing ongoing engagement with leading medical institutions in each country across the Asia-Pacific region to establish long-term relationships with major hospitals that directly benefit our clients,” Moller said.
There is growth in the CRO market in Asia due to an increase in R&D activity. According to a report published by Novotech in 2016, Asia is an ideal location for clinical trials due to its “speed, worldwide data acceptability, and cost effectiveness.”